
# **CLINICAL PHARMACIST INTERVENTIONS IN THE CRITICAL** PATIENT: EVOLUTION OF A FOUR YEAR PROJECT

#### L Fernandes<sup>1</sup>, H Melo<sup>1</sup>, MJ Rei<sup>1</sup>, A Duarte<sup>1</sup>, C Santos<sup>2</sup>, J Andrade Gomes<sup>3</sup>

<sup>1</sup>Hospital da Luz, Pharmacy, Lisbon, Portugal <sup>2</sup>Pharmacy Department Director, Luz Saúde, Lisbon, Portugal <sup>3</sup>Hospital da Luz, Intensive Care Unit, Lisbon, Portugal



#### BACKGROUND

Patients admitted to intensive care units (ICU) are at increased risk of prescription errors and related adverse events due to the critical nature of their disease, polypharmacy, use of high-risk drugs and high frequency of therapeutic changes.<sup>1, 2, 3</sup> An effective intervention to reduce this risk is the presence of a clinical pharmacist in the ICU team, contributing to the optimization of therapy and quality of service provided to the patient.<sup>4, 5, 6</sup>

Since 2011, a pharmacist integrates the multidisciplinary team for critically ill patients in the eight-bed polyvalent ICU. The post implementation evaluation showed a rate of 3.5 interventions/patient and a pharmacist interventions (PI) acceptance rate of about 70%. In order to assess the evolution of the pharmacist role, the same evaluation was conducted in 2015.

## PURPOSE

To characterize the evolution of PI after 4 years of the clinical pharmacist integration in the ICU multidisciplinary team;

• To identify major contribution areas in order to optimize therapeutics in critically ill patients.

#### **MATERIAL AND METHODS**

Pharmacist daily tasks include team-ward round and in-ward evaluation of all patient's therapeutic profiles, during the morning period. PI are then discussed with the physicians team.

• Pl are recorded in a record sheet (Figure 1) developed specifically for this purpose and already used in 2011.

Verify of multiple choices; includes demographic data of patients; medical specialty and the drug upon which intervened;

• Retrospective study: PI between March and June 2015: during this period the pharmacist validated the prescriptions of patients admitted to the ICU in a total of 59 days;

• PI were analyzed using simple statistical analysis tools of Microsoft Office Excel. The variables included were medical specialty, acceptance rate, cause, type and outcome of the PI.

Data		E1 Diminuição do custo da terapêutica
NHC		E2 Diminuição do desconforto
		E3 Diminuição do risco associado à via de administração
INTER	IVENÇÃO № ACEITE S N	E4 Diminuição do risco de toxicidade/reação adversa
		E5 Diminuição do risco de aparecimento de PS (TVP, GPS,etc.)
		E6 Aumento da efectividade
	1 Médico(a)	E7 Evitar administração de medicamento desnecessário
DCI	2	E8 Assegurar terapèutica
Obj.	Tx:	
Motiv	v. Interv:	
		OUTCOMES
		01 melhorado
CAUS		O2 não melhorado/ não agravado
C1	Alternativa terapêutica de menor custo	O3 agravado
C2	Utilização não idónea do medicamento por questões relacionadas com o medicamento	O4 prevenido
C3_1	Utilização não idónea do medicamento por questões relacionadas com a FR	O5 não prevenido
C3_2	Utilização não idónea do medicamento por questões relacionadas com a FH	O6 Promover conforto
C3_3	Utilização não idónea do medicamento por questões relacionadas com a idade	O7 Diminuição de custos directos relacionados com a terapêutica
C3_4	Utilização não idónea do medicamento por questões relacionadas com o peso	O8 Indeterminado/por apurar
C3_5	Utilização não idónea do medicamento por outras questões:	
C4	Medicamento sem indicação ou contra-indicado	
C5	Ausência terapêutica (falta de prescrição ou de adesão)	7
C6	Duplicação de terapêutica	
C7	Inefectividade da terapêutica	
C8	Duração inapropriada da terapêutica	
C9	Desconforto potencial	] .
C10	Interação Potencial	
C11	Rescião Adversa potencial/ Toxicidade	
INTER	IVENÇÃO	
11	Alteração da via de administração/ formulação	
12	Alteração de dose/ intervalo de administração	
13	Alteração da duração da terapêutica	
14	Iniciar medicamento	
15	Suspender medicamento	
16	Alteração de medicamento	
17	Sugestão de monitorização de parâmetros laboratoriais	- Data de fecher
18	Monitorização PK de fármacos	Data de fecho:

Abstract Number: CP-160

European association

HOSPITAL DA LUZ

of hospital pharmacists

## RESULTS


# 217 PI – total of 97 patients

#### Pl acceptance rate of 82%

C1 – Less expensive drug alternative C2 – Inadequate use of drug due to drug

- characteristics
- C3\_1 Inadequate use of drug due to renal function
- C3\_2 Inadequate use of drug due to liver function
- C3\_3 Inadequate use of drug related to patient age
- C3\_4 Inadequate use of drug due to patient weight
- C3\_5 Inadequate use of drug due to other reasons
- C4 Drug with no clinical indication or contraindicated
- C5 Drug absence for an existent indication
- C6 Therapeutic duplication
- C7 Decreased drug clinical efficacy
- C8 Inadequate duration of therapy
- C9 Potential patient discomfort
- C10 Potential drug interaction
- C11 Potential adverse reaction/toxicity


The most frequent cause of PI was 'Potential adverse reaction/toxicity' (18%), followed by 'Drug absence for an existent indication' (14%). The most intervened drugs regarding these two causes are shown in Tables 1 and 2.



Drug	No. Pl
Vancomycin	22
Gentamicin	11
Enoxaparin	10
Dipyrone	8
Meropenem	6
regarding the cause 'Po	ost intervened tential adverse
Table 1 – Drugs mo regarding the cause 'Po reaction/toxicity'. Drug	
regarding the cause 'Po reaction/toxicity'.	tential adverse
regarding the cause 'Po reaction/toxicity'. Drug Acetylsalicylic acid	tential adverse No. Pl
regarding the cause 'Po reaction/toxicity'. Drug	tential adverse No. PI 6
regarding the cause 'Po reaction/toxicity'. Drug Acetylsalicylic acid Enoxaparin Rosuvastatin	tential adverse No. PI 6 5
regarding the cause 'Po reaction/toxicity'. Drug Acetylsalicylic acid Enoxaparin	tential adverse No. Pl 6 5 5

regarding the cause 'Drug absence for an existent indication '

The medical specialties with more PI were Internal Medicine, Cardiac Surgery and General Surgery.




The ten pharmacotherapeutic groups with more PI were:

A04-ANTIEMETICS AND ANTINAUSEANTS

#### I1 – Administration route/ pharmaceutical form

#### The most frequently suggested PI were 'Dose/dosing'



#### CONCLUSIONS

• Pharmacists integration in the multidisciplinary ICU team and their technical contribution are clearly positive, regarding the number of pharmacist interventions (PI) and their acceptance rate (> 80%);

In comparison to the results shown after the implementation of the project in 2011, there is a greater diversity of intervention causes and the main areas of activity are: the absence of important home therapy like secondary prophylaxis of cardiac and cerebrovascular events and/or antidepressant and antipsychotic medication; prophylactic therapy of in-hospital events such as venous thromboembolism and stress gastropathy, and prevention of adverse reactions and toxicity associated with narrow therapeutic index drugs;

Interesting future challenges will be to explore the outcome measures that can better translate the ICU as well as to have the PI classified with a scale of clinical impact by one or a group of ICU clinicians.

#### REFERENCES

<sup>1</sup> Klopotowska, Joanna, et al. "On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study." Critical Care, 2010: 14:R174. <sup>2</sup> Rothschild, Jeffrey M., et al. "The Critical Care Safety Study: The incidence and nature of adverse events and serious medical errors in intensive care." Critical Care Medicine, 2005: 1694-1700. <sup>3</sup> Cullen DJ, Sweitzer BJ, Bates DW, et al. "Preventable adverse drug events in hospitalized patients: A comparative study of intensive care units and general care units." Critical Care Medicine, 1997; 25:1289–1297 <sup>4</sup> Ho, Claudia K, Vincent H Mabasa, Vivian WY Leung, Douglas L Malyuk, e Jerrold L Perrott. "Assessment of Clinical Pharmacy Interventions in the Intensive Care Unit." The Canadian Journal of Hospital Pharmacy, 2013: 212-8.

<sup>5</sup> Leape LL, Cullen DJ, Clapp MD, et al. "Pharmacist participation on physician rounds and adverse drug events in the intensive care unit." JAMA, 1999; 282:267–270

<sup>6</sup> Kane SL, Weber RJ, Dasta JF. "The impact of critical care pharmacists on enhancing patient outcomes." Intensive Care Medicine, 2003; 29:691–698